"Dueling" analgesic ads are "distasteful and regrettable misuse of science" -- NDAC's Juhl.
This article was originally published in The Tan Sheet
Executive Summary
"DUELING" ANALGESIC ADS "DISTASTEFUL AND REGRETTABLE MISUSE OF SCIENCE" by "all of the parties involved," Nonprescription Drug Advisory Committee Chairman Randy Juhl, PhD, University of Pittsburgh, commented at a recent meeting on pharmaceutical outcomes research. Sponsored by the Center for Pharmaceutical Outcomes Research, the meeting was held March 31-April 2 at the University of North Carolina, Chapel Hill.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning